(Total Views: 647)
Posted On: 08/05/2020 1:44:53 PM
Post# of 153767
The world will likely need multiple therapeutics. Im sure a good deal of the investors here are concerned about competition and vaccines, etc.
I'm not, because I didn't invest in this company for COVID. Its a bonus. In the long term, the value of CYDY is in Cancer, GvHD, HIV, Nash, and many other indications.
With respect to COVID, and other viruses that cause pneumonia and cytokine storm, Leronlimab (IMO) will be the drug of choice eventually because it is universally effective against any malady that causes a cytokine storm.
From an investment standpoint, If we fail to capitalize on COVID it just pushed out the timeframe for me of when this stock will be properly valued.
I'm not, because I didn't invest in this company for COVID. Its a bonus. In the long term, the value of CYDY is in Cancer, GvHD, HIV, Nash, and many other indications.
With respect to COVID, and other viruses that cause pneumonia and cytokine storm, Leronlimab (IMO) will be the drug of choice eventually because it is universally effective against any malady that causes a cytokine storm.
From an investment standpoint, If we fail to capitalize on COVID it just pushed out the timeframe for me of when this stock will be properly valued.
(3)
(0)
